FDA signals crackdown on controversial painkiller

04:31 EST 15 Nov 2017 | Pharmafile

Scott Gottlieb, the FDA’s Commissioner, issued an advisory about the medicinal plant-product known as kratom. The plant is known to act as a stimulant in low-doses and has opioid-like effects in higher doses, but whether it is directly harmful is a matter of serious debate.

The plant has been used in Asia, where it originates, as a natural remedy for numerous ailments and, like the coca plant in Central and South America, has been used as a stimulant by labourers to maintain energy for centuries.

read more

Original Article: FDA signals crackdown on controversial painkiller


More From BioPortfolio on "FDA signals crackdown on controversial painkiller"

Quick Search


Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...